Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Families-At-risk for Interstitial Lung Disease Study (FAR-ILD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03641742
Recruitment Status : Recruiting
First Posted : August 22, 2018
Last Update Posted : August 22, 2018
Sponsor:
Collaborators:
University of Washington
Weill Medical College of Cornell University
University of Iowa
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
David J. Lederer, M.D., Columbia University

Brief Summary:
The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia. While previously considered to be rare, a recent nationwide study found that idiopathic pulmonary fibrosis (IPF), a fibrotic ILD with a median survival of only 3.8 years, affects nearly 0.5% of older adults in the U.S. While pirfenidone and nintedanib slow the progression of IPF, neither reverses fibrosis nor prevents progression of the disease,and no studies to date have tested interventions that prevent the development of fibrotic ILDs.

Condition or disease
Interstitial Lung Disease Idiopathic Pulmonary Fibrosis

Detailed Description:

The NHLBI has prioritized research focused on the primary prevention of chronic lung diseases, including ILD. The overall goal of this study is to conduct studies preparatory to and requisite for the testing of ILD preventative interventions.

In the current study, the investigators propose to examine the pulmonary histopathology and biology of early subclinical ILD in healthy adults with a first-degree relative with clinically diagnosed ILD. There are two currently accepted computed tomographic (CT)-based phenotypes of subclinical ILD: high attenuation areas (HAAs) and interstitial lung abnormalities (ILA). Investigators from Columbia University Medical Center have previously shown that HAA has strong construct validity as an imaging biomarker of early subclinical alveolar inflammation and fibrosis among community-dwelling adults using the Multi-Ethnic Study of Atherosclerosis (MESA), an ongoing NHLBI-funded prospective cohort study of 6,814 adults age 45 and older at enrollment in 2000-02. Investigators found that greater HAA at baseline was independently associated with reduced lung function and exercise capacity at 5-year follow-up, exertional dyspnea at 10-year follow-up, and elevated serum levels of matrix metalloproteinase-7 (MMP-7) and interleukin-6 (IL-6). ILA is a distinct qualitative and visually-identified early ILD phenotype on CT that has also shown strong construct validity for ILD. Neither HAA nor ILA has been validated histopathologically.

The lipoprotein substudy will examine the role of high density lipoproteins in patients with ILD. Patients with IPF have previously been shown to have low levels of high density lipoprotein (HDL) and high levels of low density lipoprotein (LDL). Investigators have previously shown that high levels of high-density cholesterol (HDL-C) are associated with a reduction in lung injury, inflammation and fibrosis (subclinical ILD) on CT in community-dwelling adults enrolled in the Multi-Ethnic Study of Atherosclerosis. These data are consistent with animal model data showing that treatment with apolipoprotein A-I (ApoA-I; the main component of HDL) attenuates lung fibrosis. Investigators at Columbia University Medical Center are therefore proposing to examine the associations of HDL and its main components (apolipoprotein A-I, apolipoprotein A-II, and paraoxonase-1) with clinical outcomes (FVC decline, death, lung transplantation and respiratory hospitalizations) and serum biomarkers of lung injury, inflammation and remodeling (SP-A, MMP-7, ICAM-1, IL-1, IL-18) in patients with ILD. Investigators will also explore the structure (using quantitative proteomics) and function (using a macrophage efflux assay and paraoxonase-1 activity assay) of HDL particles in adults with ILD and first-degree family members with subclinical ILD.

Obstructive sleep apnea (OSA) is highly prevalent among adults with interstitial lung disease (ILD) and maybe a risk factor based on our previous studies from MESA (https://www.mesa-nhlbi.org/) and other research studies completed at Columbia University Medical Center. Therefore, the investigators will examine the association between OSA and sub-clinical ILD in at-risk adults.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 800 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Families-At-risk for Interstitial Lung Disease Study
Actual Study Start Date : January 15, 2018
Estimated Primary Completion Date : October 1, 2035
Estimated Study Completion Date : October 1, 2037


Group/Cohort
FAR-ILD Proband Participants
There will be no interventions administered to this group, only data collection.
FAR-ILD "At-Risk" Participants
There will be no interventions administered to this group, only data collection



Primary Outcome Measures :
  1. Number of subjects with histopathologically validated HAA or ILA [ Time Frame: Up to 20 years ]
    The visual identification of the presence of HAA or ILA on CT scan by a radiologist or pulmonologist.


Biospecimen Retention:   Samples With DNA
  • Tissue samples
  • Airway Brushings
  • Urine
  • Bronchoalveolar Lavage Fluid
  • Buccal swab and or saliva; only if blood is unavailable.
  • Blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adult participants with and without a diagnosis of Interstitial Lung Disease. Adult participants with a diagnosis of interstitial lung disease as per American Thoracic Society (ATS) guidelines. Adult participants with a first-degree relative with a clinical diagnosis of interstitial lung disease. Adult participants who are at least 50 years of age with a smoking history of a minimum of 1 pack per day.
Criteria

Inclusion Criteria: For "At Risk" participants without clinical ILD

  • Age 35 years or older, however subjects who are 40 years old and above will undergo HRCT and subjects age 40-65 years old will be eligible to undergo bronchoscopy
  • First-degree relative with one of the following clinical diagnoses:
  • Idiopathic Pulmonary Fibrosis
  • Idiopathic Non-Specific Interstitial Lung Disease (with fibrosis)
  • Chronic Hypersensitivity Pneumonitis (with fibrosis)
  • Unclassifiable Idiopathic Interstitial Pneumonia (with fibrosis)
  • Patients with any ILD characterized by fibrosis on CT chest scan
  • Ability to provide informed consent

Inclusion Criteria: For "At Risk Smoker" participants without clinical ILD

  • At least 50 years of age
  • Smoked at least 1 pack a day for 30 years

Exclusion Criteria: For "At-Risk" participants without clinical ILD

  • Known history of interstitial lung disease
  • History of illicit drug use within the past year.
  • Lower respiratory tract infection in the past 90 days.
  • History of chest CT scan in the past year.
  • Known history of heart failure or chronic kidney or liver disease.
  • Pregnancy or Lactation

Inclusion Criteria: For "Proband" participants with clinical ILD Age 18 years or older

  • Has one of the following clinical diagnoses as per ATS guidelines:
  • Idiopathic Pulmonary Fibrosis
  • Idiopathic Non-Specific Interstitial Lung Disease (with fibrosis)
  • Chronic Hypersensitivity Pneumonitis (with fibrosis)
  • Unclassifiable Idiopathic Interstitial Pneumonia (with fibrosis)
  • Patient with any ILD characterized by fibrosis on CT chest scan
  • Ability to provide informed consent

Exclusion Criteria: For "Proband" participants with clinical ILD

  • No Living 1st degree relatives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03641742


Contacts
Layout table for location contacts
Contact: David J Lederer, MD 212-305-8203 dl427@cumc.columbia.edu
Contact: Atif Choudhury, BA 212-342-4551 mac2463@cumc.columbia.edu

Locations
Layout table for location information
United States, New York
Columbia University Medical Center Recruiting
Manhattan, New York, United States, 10032
Contact: David Lederer, Medical    212-305-8203    dl427@cumc.columbia.edu   
Contact: M. Atif Choudhury, BA    212.342.4551    mac2463@cumc.columbia.edu   
Principal Investigator: David J Lederer, MD         
Sub-Investigator: Nina Patel, MD         
Sub-Investigator: Anna Podolanczuk, MD         
Sub-Investigator: John Kim, MD         
Sub-Investigator: Wellington Cardoso, MD         
Sub-Investigator: Anjali Saqi, MD         
Sub-Investigator: William Bulam, MD         
Sub-Investigator: David Goldstein, MD         
Sponsors and Collaborators
Columbia University
University of Washington
Weill Medical College of Cornell University
University of Iowa
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: David Lederer, MD Associate Professor of Medicine and Epidemiology (in Pediatrics), Dept of Medicine Pulmonary

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: David J. Lederer, M.D., Associate Professor of Medicine and Epidemiology, Columbia University
ClinicalTrials.gov Identifier: NCT03641742     History of Changes
Other Study ID Numbers: AAAR1916
2R01HL103676-05 ( U.S. NIH Grant/Contract )
First Posted: August 22, 2018    Key Record Dates
Last Update Posted: August 22, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Researchers will be required to submit a written request to Dr. Lederer describing the use of the data. The researcher must also document institutional review board (IRB) approval. No identifiable information will be released.
Access Criteria: De-identified data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by David J. Lederer, M.D., Columbia University:
Interstitial Lung Disease
Pulmonary Fibrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Fibrosis
Pathologic Processes
Respiratory Tract Diseases